US/UK/Canada

Share

Contacts

  • Bronwyn Brophy O'Connor

    CEO


    Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Pär Ihrskog

    CFO


    Vitrolife AB (publ), Box 9080, 400 92 Göteborg, Sweden
    http://www.vitrolifegroup.com
  • Amelie Wilson

    Investor Relations


  • Vitrolife AB
    +46 (0)31 721 80 00
    +46 (0)31 721 80 99
    http://www.vitrolifegroup.com

    • Links

    Pick a time period -
    Tags ( Active)

    Vitrolife Group appoints Olivier Desmarets as Chief Operations Officer following Ermanno Sironi’s retirement

    Vitrolife Group today announces the appointment of Olivier Desmarets as Chief Operations Officer (COO), effective 1 June 2026, following the retirement of Ermanno Sironi. In this role, Olivier Desmarets will be responsible for leading the company’s global operations, including Manufacturing, Labs, Supply chain & Procurement, Quality, Customer Care, IT and further strengthening operational performance across the organisation. Ermanno Sironi has played a key role in advancing Vitrolife Group’s operational capabilities and driving several important transformation initiatives over the past

    CEO Bronwyn Brophy O'Connor has decided to leave Vitrolife Group

    Vitrolife AB (publ) today announces that CEO Bronwyn Brophy O'Connor has decided to leave the company to assume a CEO role in a different area of the medtech industry. Vitrolife Group's Board has received Bronwyn's resignation and will immediately begin the recruitment process for a new CEO. Bronwyn will remain in her role during her notice period for up to 12 months to ensure a smooth transition to her successor. The Board, supported by international recruitment specialists, will immediately initiate the search for Bronwyn’s successor who can strategically guide and advance the company

    Report from the Annual General Meeting of Vitrolife AB (publ)

    The Annual General Meeting of Vitrolife AB (publ) was held today on Tuesday 5 May 2026. The Annual General Meeting resolved in accordance with all proposals presented by the Board and the Nomination Committee. The Annual General Meeting resolved to re-elect the Board members Henrik Blomquist, Karen Lykke Sørensen, Pia Marions and Jón Sigurdsson, and to elect Nicklas Hansen and David T. Hansen as new Board members. Jón Sigurdsson was re-elected as Chairman of the Board. The Annual General Meeting adopted the Income Statements and Balance Sheets for the parent company and the group and

    Interim report Q1, 2026: Strong growth in Consumables and Technologies

    First quarter  ·Sales of SEK 807 (842) million, an increase of 5% in local currencies and 4% decrease in SEK.   ·Sales per region, in local currencies, were -1% in EMEA, +11% in Americas and +7% in APAC.   ·Sales per product group, in local currencies were +9% in Consumables, +11% in Technologies and -1% in Genetics.   ·Gross margin increase to 59.9% (57.4).   ·Earnings before depreciation and amortisation (EBITDA) amounted to SEK 251 (257) million, resulting in an EBITDA margin of 31.1% (30.6).   ·Net income amounted to SEK 101 (100) million,

    Invitation to Vitrolife Group's presentation of the Q1 2026 interim report

    Vitrolife AB (publ) will publish its Q1 2026 interim report on Thursday, 23 April 2026 at 08:00 am CET. A conference call for investors, analysts and financial media will be held at 10:00 am CET the same day.  The presentation will be held in English by Bronwyn Brophy O’Connor, CEO, and Pär Ihrskog, CFO. The conference call will begin with a presentation of the report followed by a question-and-answer session. The presentation material will be available prior to the start of the conference call on the Vitrolife Group website www.vitrolifegroup.com.  To follow the webcast, please use

    Notice of the Annual General Meeting of Vitrolife AB (publ)

    The Annual General Meeting of Vitrolife AB (publ), 556354–3452, will be held on Tuesday 5 May 2026 at 17:00 CEST at Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. Registration for the Annual General Meeting will commence at 16:30 CEST. The Board has decided that shareholders may exercise their voting rights at the Annual General Meeting also by postal voting in advance, in accordance with the provisions of the Articles of Association. The notice is attached to this press release, and is also available at the company's website, www.vitrolifegroup.com.

    The Nomination Committee proposes two new Board members

    Vitrolife AB (publ) ("Vitrolife") today announced that its Nomination Committee proposes the election of Nicklas Hansen and David T. Hansen as new Board members. The Committee further proposes the re-election of Jón Sigurdsson as Chairman of the Board, as well as all current Board members except Lars Holmqvist, who has decided not to stand for re-election at the 2026 Annual General Meeting. Nicklas Hansen is Chief Investment Officer at Vitrolife's largest shareholder, William Demant Invest A/S, where he is responsible for its investment portfolio. He has held several positions at William

    Vitrolife Group has today published its Annual and Sustainability Report for 2025

    The Annual and Sustainability Report is now available digitally in English and Swedish at www.vitrolifegroup.com. The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedish. Vitrolife Group has chosen not to print or distribute a hard copy of the Annual Report. Those who are unable to access the Annual Report digitally can request a print-out of the Annual Report by contacting Vitrolife Group at investors@vitrolife.com or call +46 (0) 31 721 80 00. Gothenburg, SwedenMarch 26, 2026VITROLIFE AB (publ)

    Fourth quarter and full year report 2025

    Fourth quarter •          Sales of SEK 891 (959) million, organic growth in local currencies excluding discontinued business* were 6%, 3% growth in local currencies and 7% decrease in SEK, due to a significant currency impact of -10%. •          Sales per region, in local currencies, were -1% in EMEA excluding discontinued business, +9% in Americas and +10% in APAC. •          Sales per product group, in local currencies excluding discontinued business, were +10% in Consumables, +6% in Technologies and +1% in Genetics. •          Gross margin decreased to 58.0% (61.1). Gross

    Invitation to Vitrolife Group’s presentation of the fourth quarter and full year report 2025

    Vitrolife AB (publ) will publish its fourth quarter and full year report 2025 on Tuesday, 3 February 2026 at 08:00 am CET. A conference call for investors, analysts and financial media will be held at 10:00 am CET the same day.  The presentation will be held in English by Bronwyn Brophy O’Connor, CEO, and Pär Ihrskog, CFO. The conference call will begin with a presentation of the report followed by a question-and-answer session. The presentation material will be available prior to the start of the conference call on the Vitrolife Group website www.vitrolifegroup.com.  To follow the

    Vitrolife announces genetic services restructuring program targeting annualised savings of 65 MSEK and recognises a 5.4 BSEK goodwill impairment

    Vitrolife AB (publ) (“Vitrolife”) today announced that following a strategic review it will execute a restructuring program of its genetic services business. The program is targeting annualised savings of SEK 65 million, expected to have a positive impact in the first half of 2026, and to reach full effect by the end of the third quarter 2026. Furthermore, Vitrolife will record a goodwill impairment of SEK 5.4 billion in Q4 2025, related to the Igenomix acquisition.As part of the restructuring program, Vitrolife has decided to discontinue two genetic test lines (GPDx and NACE). An agreement

    Nomination committee of Vitrolife AB (publ) for the Annual General Meeting 2026

    In accordance with the Nomination Committee Charter adopted at the Annual General Meeting 2025, the members who, together with the Chair of the Board, constitute the Nomination Committee in preparation of the Annual General Meeting 2026 have been elected.The Nomination Committee consists of:Niels Jacobsen, appointed by William Demant Invest A/SPatrik Tigerschiöld, appointed by Bure Equity ABPatricia Hedelius, appointed by AMF Fonder & PensionJón Sigurdsson, Chairman of the Board The Annual General Meeting of Vitrolife AB will be held in Gothenburg on 6 May 2026. Shareholders

    Interim report Q3, 2025: Strong growth in Americas

    Third quarter · Sales of SEK 835 (867) million, 3% growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -7%. Organic growth in local currencies excluding discontinued business* was 5%. · Sales per region, in local currencies, were -2% in EMEA, +4% excluding discontinued business, +11% in Americas and +1% in APAC. · Sales per product group, in local currencies excluding discontinued business, were +7 in Consumables, +8% in Technologies and +3% in Genetics. · Sales per product group, in local currencies, were +4% in Consumables, +8% in

    Invitation to Vitrolife Group’s presentation of the Q3 2025 interim report

    Vitrolife AB (publ) will publish its Q3 2025 interim report on Thursday, 23 October 2025 at 08:00 am CEST. A conference call for investors, analysts and financial media will be held at 10:00 am CEST the same day. The presentation will be held in English by Bronwyn Brophy O’Connor, CEO, and Pär Ihrskog, CFO. The conference call will begin with a presentation of the report followed by a question-and-answer session. The presentation material will be available prior to the start of the conference call on the Vitrolife Group website www.vitrolifegroup.com. To follow the webcast, please use

    Interim report Q2, 2025: Strong performance across Consumables

    Second quarter · Sales of SEK 871 (941) million, a flat growth in local currencies and a 7% decrease in SEK, due to a significant currency impact of -8%. Organic growth in local currencies excluding discontinued business was 3%. · Sales per region, in local currencies was -3% in EMEA, +5% excluding discontinued business, +5% in Americas and 0% in APAC. · Sales per product group, in local currencies excluding discontinued business was +9% in Consumables, -6% in Technologies and +3% in Genetics. · Sales per product group, in local currencies was +5% in Consumables, -8% in

    Invitation to Vitrolife Group’s presentation of the Q2 2025 interim report

    Vitrolife AB (publ) will publish its Q2 2025 interim report on Thursday, 17 July 2025 at 08:00 am CEST. A conference call for investors, analysts and financial media will be held at 10:00 am CEST the same day.The presentation will be held in English by Bronwyn Brophy O’Connor, CEO, and Helena Wennerström, acting CFO. The conference call will begin with a presentation of the report followed by a question-and-answer session. The presentation material will be available prior to the start of the conference call on the Vitrolife Group website www.vitrolifegroup.com. 

    Vitrolife Group completes refinancing facility backed by leading Nordic Banks

    Vitrolife AB (publ) has today renewed and signed a loan agreement of EUR 300 million comprising of term loan and revolving credit facility. The term loan will be used to refinance existing debt and the revolving credit facility will be available for general corporate purposes.The loan agreement is backed by leading Nordic banks, with Nordea and SEB renewing their commitments and AB Svensk Exportkredit joining as a new lender, underscoring the Vitrolife Group’s strong credit profile and focus on export. The loan agreement has a tenor of three-years and includes two one-year extension options.

    Vitrolife AB (publ) becomes lead investor in AutoIVF

    The Vitrolife Group today announces it has become a leading investor in AutoIVF. This strategic investment aligns with our corporate strategy of improving affordability and access to IVF to patients around the world.AutoIVF, is an early-stage MedTech company with the aim to make IVF more accessible, affordable and efficient. Its technology, OvaReady™, is a groundbreaking automated system that simplifies and enhances egg retrieval and preparation, enabling high-quality fertility services in the current IVF process and also supports decentralising the egg retrieval process outside traditional

    Report from Annual General Meeting of Vitrolife AB (publ)

    At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: · Resolution in accordance with the Board’s proposed dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day. · Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee’s proposal. Jón Sigurdsson was elected Chairman of the Board. · Remuneration to the Board members is proposed to be in total SEK 3 670 000 (3 300 000) of which

    Report from Annual General Meeting of Vitrolife AB (publ)

    At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: · Resolution in accordance with the Board’s proposed dividend of SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day. · Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee’s proposal. Jón Sigurdsson was elected Chairman of the Board. · Remuneration to the Board members is proposed to be in total SEK 3 670 000 (3 300 000) of which SEK 1

    Interim report Q1, 2025: Strong performance in EMEA

    First quarter  · Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%.  · Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC.  · Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics.  · Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics.  · Gross margin

    The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer

    Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master’s degree in business administration.  “We are delighted to welcome Pär Ihrskog to the Vitrolife Group as CFO. His extensive financial expertise, combined with a proven

    Conference call interim report

    Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q1 2025. The presentation will be held in English.Time: Thursday 24 April, 2025 at 10.00 a.m. CET.  To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy  Register for the call here (

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe